Indonesia Brugada Syndrome Market Analysis

Indonesia Brugada Syndrome Market Executive Summary

The Indonesia Brugada Syndrome Market is at around $7.2 Mn in 2023 and is projected to reach $12.2 Mn in 2030, exhibiting a CAGR of 7.8% during the forecast period.

Brugada syndrome is a rare, but potentially threatening, genetic condition that causes abnormal electrical activity in the heart, leading to an increased risk of sudden cardiac death. People with Brugada syndrome have an increased risk of irregular heart rhythms beginning in the lower chambers of the heart, i.e., the ventricles. Common signs and symptoms associated with Brugada Syndrome include dizziness, fainting, gasping and laboured breathing, particularly at night, irregular heartbeats or palpitations, extremely fast and chaotic heartbeat, and seizures. The risk factors for Brugada syndrome include family history of Brugada syndrome, being male, race, and fever.

Indonesia has the highest share of cardiovascular diseases (CVDs) to total disease burden in Southeast Asia, which is 21.34% of total Disability-adjusted life years (DALYs). The Indonesia Brugada Syndrome Market is driven by significant factors such as growing prevalence of cardiovascular diseases, geriatric population, and advancements in genetic testing. However, high cost of treatment, limited awareness, and limited R&D restrict the growth and potential of the market.

The major players of the Indonesia Brugada Syndrome Market are Kalbe Farma, Dexa Medica, Kimia Farma, Tempo Scan Pacific, Phapros, and Medtronic, among others.

Market Dynamics

Market Growth Drivers

Growing Prevalence of Cardiovascular Diseases: Roughly a third of all deaths in Indonesia are attributable to CVD, with stroke and coronary heart disease being the leading causes of mortality in the country. The surge in cardiovascular diseases linked to aging, lifestyle factors, and conditions like hypertension and diabetes has increased focus on rare genetic disorders such as Brugada syndrome. This increased attention is fuelling investments in research, diagnostic tools, and advanced treatments for Brugada syndrome. As healthcare systems prioritize comprehensive cardiovascular care, the demand for effective management and therapies for this condition is on the rise, driving market expansion.

Geriatric Population: As of 2022, Indonesia’s senior population comprised of 19 Mn elderly citizens. As people age, their risk of developing heart conditions, including Brugada syndrome, rises, expanding the potential patient base. Additionally, older adults are more prone to complications from arrhythmias, highlighting the need for effective preventative measures and treatments. This demographic trend is expected to increase the demand for diagnostic tools, therapeutic interventions, and patient monitoring devices tailored to the growing number of elderly individuals with Brugada syndrome, thereby boosting market growth.

Advancements in Genetic Testing: The advanced technologies enable the identification of specific genetic mutations linked to the arrhythmia, leading to earlier and more precise diagnoses. Early detection is vital for implementing preventive measures and mitigating the risk of sudden cardiac death. Additionally, genetic testing supports risk assessment for family members, promoting proactive screening and management. As genetic testing becomes more accessible and affordable, it is expected to boost Brugada Syndrome Market growth by increasing the number of diagnosed patients and heightening demand for associated treatments, devices, and monitoring services.

Market Restraints

High Cost of Treatment: The significant cost of treatment and diagnostic tools for Brugada syndrome represents a major challenge to market growth. Advanced treatments, including implantable cardioverter defibrillators (ICDs) and specialized genetic testing, are often prohibitively expensive, making them inaccessible to many patients, particularly those from low- and middle-income backgrounds. This financial obstacle restricts access to essential care and treatment, impeding widespread diagnosis, early intervention, and effective management of Brugada syndrome, which in turn slows the market's development.

Limited Awareness: Limited awareness of Brugada syndrome in Indonesia presents a major challenge to market growth. The general lack of understanding about the condition among the public, healthcare providers, and patients results in delayed diagnoses, missed prevention opportunities, and subpar management. This insufficient awareness decreases the demand for diagnostic tests, treatments, and patient support services, which in turn hinders the overall development of the Brugada syndrome market in the country.

Limited R&D: The restricted research and development in Brugada syndrome notably impedes market growth. Due to its rarity, the condition garners less investment compared to more prevalent cardiovascular diseases, leading to slower advancements in understanding the disease, developing new diagnostic tools, and creating innovative treatments. As a result, medical breakthroughs are infrequent, limiting the availability of effective therapies and diagnostic methods, and ultimately constraining the market growth for Brugada syndrome.

Regulatory Landscape and Reimbursement Scenario

In Indonesia, the regulatory agency is called the National Agency of Drug and Food Control (NADFC), also known by its Indonesian name, Badan Pengawas Obat dan Makanan (BPOM) which operates under the Ministry of Health. It plays a critical role in ensuring the safety, efficacy, and quality of pharmaceuticals available in the nation.

The NADFC conducts detailed review and analysis of the applications from pharmaceutical companies to register and market the new drugs. It includes a thorough evaluation of the safety, efficacy, and quality of pharmaceutical products. After the NADFC is ensured of these characteristics, does it allow the drugs to be marketed. The NADFC is also responsible for post-marketing surveillance of the drugs in case of any reporting of adverse drug reactions.

Indonesia’s healthcare reimbursement system is a complex mix of public and private insurance schemes. The mandated national health insurance scheme in Indonesia is called Jaminan Kesehatan Nasional (JKN), or National Health Insurance. It attempts to give access to basic healthcare and covers a sizable section of the populace. The JKN reimburses healthcare costs for outpatient and inpatient services at the designated healthcare facilities. For the private sector, compared to the JKN, private health insurance plans may provide greater coverage and better reimbursement rates.

Competitive Landscape

Key Players

Here are some of the major key players in the Indonesia Brugada Syndrome Market:

• Kalbe Farma
• Dexa Medica
• Kimia Farma
• Tempo Scan Pacific
• Phapros
• Medtronic
• Abbott Laboratories
• Johnson & Johnson
• Siemens Healthcare
• F. Hoffmann-La Roche